


## Cedirogant

<b>Cat. No.:</b>	HY-137434		
<b>CAS No.:</b>	2055496-11-0		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>20</sub> Cl <sub>3</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	547.78		
<b>Target:</b>	ROR		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 250 mg/mL (456.39 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	<b>1 mM</b>	1.8256 mL	9.1278 mL	18.2555 mL
	<b>5 mM</b>	0.3651 mL	1.8256 mL	3.6511 mL
	<b>10 mM</b>	0.1826 mL	0.9128 mL	1.8256 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution</li> </ol>			

### BIOLOGICAL ACTIVITY

<b>Description</b>	Cedirogant (ABBV-157) is an orally active ROR $\gamma$ t inverse agonist. Cedirogant can be used for psoriasis research <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	ROR $\gamma$ t <sup>[1]</sup>
<b>In Vitro</b>	<p>The transcription factor retinoic acid-related orphan receptor gamma t (ROR<math>\gamma</math>t) has been identified as the master regulator of TH17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Cedirogant (ABBV-157) has the potential for chronic plaque psoriasis research<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

---

## REFERENCES

---

[1]. Elena Campione, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737.

[2]. Christian Gege. Retinoic acid-related orphan receptor gamma t (ROR $\gamma$ t) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently? Expert Opin Drug Discov. 2021 Jul 7;1-19.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA